Inogen Inc (NASDAQ:INGN) Short Interest Update

Share on StockTwits

Inogen Inc (NASDAQ:INGN) was the target of a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 3,538,100 shares, a decline of 10.7% from the May 30th total of 3,962,700 shares. Currently, 19.6% of the shares of the company are short sold. Based on an average trading volume of 584,700 shares, the days-to-cover ratio is presently 6.1 days.

INGN has been the topic of a number of recent analyst reports. Needham & Company LLC upgraded shares of Smart Global from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a research note on Friday, June 28th. Stifel Nicolaus upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the stock from $11.00 to $17.00 in a research note on Wednesday, May 8th. JPMorgan Chase & Co. boosted their price target on shares of from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the stock an “overweight” rating in a research note on Wednesday, July 3rd. Finally, BidaskClub lowered shares of Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, June 27th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Inogen currently has a consensus rating of “Hold” and an average price target of $117.60.

Institutional investors have recently made changes to their positions in the business. Marshall Wace LLP lifted its holdings in Inogen by 180.2% during the 1st quarter. Marshall Wace LLP now owns 55,580 shares of the medical technology company’s stock valued at $5,301,000 after purchasing an additional 35,747 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Inogen by 8.6% during the 4th quarter. Geode Capital Management LLC now owns 205,160 shares of the medical technology company’s stock valued at $25,474,000 after purchasing an additional 16,183 shares during the last quarter. Legal & General Group Plc lifted its holdings in Inogen by 3.9% during the 4th quarter. Legal & General Group Plc now owns 17,963 shares of the medical technology company’s stock valued at $2,230,000 after purchasing an additional 668 shares during the last quarter. Renaissance Group LLC acquired a new stake in Inogen during the 1st quarter valued at $428,000. Finally, MetLife Investment Advisors LLC lifted its holdings in Inogen by 52.3% during the 4th quarter. MetLife Investment Advisors LLC now owns 18,341 shares of the medical technology company’s stock valued at $2,277,000 after purchasing an additional 6,302 shares during the last quarter. 98.61% of the stock is owned by institutional investors and hedge funds.

NASDAQ:INGN traded up $0.51 during trading hours on Friday, reaching $62.68. 244,170 shares of the stock were exchanged, compared to its average volume of 420,756. Inogen has a twelve month low of $61.35 and a twelve month high of $287.79. The company has a current ratio of 7.35, a quick ratio of 6.70 and a debt-to-equity ratio of 0.02. The company’s 50 day simple moving average is $66.30. The stock has a market capitalization of $1.37 billion, a PE ratio of 27.25, a PEG ratio of 2.48 and a beta of 1.45.

Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, May 7th. The medical technology company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.05). The company had revenue of $90.20 million during the quarter, compared to analyst estimates of $89.69 million. Inogen had a net margin of 12.56% and a return on equity of 15.59%. The company’s quarterly revenue was up 14.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.48 EPS. Analysts forecast that Inogen will post 1.63 EPS for the current year.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Read More: Trading Stocks – What are percentage gainers?

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Lonestar Resources US Inc  Director Randy L. Wolsey Purchases 5,000 Shares
Lonestar Resources US Inc Director Randy L. Wolsey Purchases 5,000 Shares
David D. O’toole Buys 1,000 Shares of Opiant Pharmaceuticals Inc  Stock
David D. O’toole Buys 1,000 Shares of Opiant Pharmaceuticals Inc Stock
FinTech Acquisition Corp. III  Trading Down 0.7%
FinTech Acquisition Corp. III Trading Down 0.7%
ICSGlobal  Trading Up 6.5%
ICSGlobal Trading Up 6.5%
Trimantium Growthops   Shares Down 19.6%
Trimantium Growthops Shares Down 19.6%
Replimune Group  Upgraded at ValuEngine
Replimune Group Upgraded at ValuEngine


 
© 2006-2019 Zolmax.